Decitabine

製品コードS1200 別名:Deoxycytidine

Decitabine化学構造

分子量(MW):228.21

Decitabine is a DNA methyltransferase inhibitor, incorporating into DNA and resulting in hypomethylation of DNA and intra-S-phase arrest of DNA replication. It is used to treat myelodysplastic syndrome (MDS).

サイズ 価格(税別)  
In DMSO JPY 27700
JPY 16900
JPY 30200
JPY 55100
JPY 96600
最寄りの販売代理店を探す

お探しのディーラーが見当たらない場合は直接こちらのメールアドレスまでお問い合わせください:[email protected]

バルク問合せ

製品安全説明書

DNA Methyltransferase阻害剤の選択性比較

生物活性

製品説明 Decitabine is a DNA methyltransferase inhibitor, incorporating into DNA and resulting in hypomethylation of DNA and intra-S-phase arrest of DNA replication. It is used to treat myelodysplastic syndrome (MDS).
ターゲット
DNA methylation [1]
(HL-60, KG1a cells)
体外試験

Decitabine inhibits cell growth in a dose and time-dependent manner with IC50 of approximately 438 nM and 43.8 nM for 72 hours and 96 hours exposure in HL-60 and KG1a leukemic cells, respectively. [1] A recent study shows that Decitabine exhibits high anti-proliferative and pro-apoptotic activity against anaplastic large cell lymphoma (ALCL), and inhibits [3H]–thymidine uptake in KARPAS-299 cells with EC50 of 0.49 μM. [2]

細胞データ
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID
Eca109 M3;UWWZ2dmO2aX;uJGF{e2G7 MVuwMlXDqM7:TR?= MoL3NlQhcA>? MmDJe4F1\XJ? NUG2OmExdW:mdXzheIV{KHSqZTDn[Y5mKGW6cILld5Nqd25ib3[gUWFITS2DIH3lcYJmenN? NIXNUmIzPTF{M{C4Ni=>
Eca109 M2TPSGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M3HueVAvPS9{LkWvOUDPxE1? Mom5NlQwPDhxN{KgbC=> M1XtSJdifGW{ M2DQNolvcGmkaYTzJINmdGxiZ4Lve5RpKGmwIHLveIgh\G:|ZT2gZY5lKHSrbXWtJIRmeGWwZHXueEBu[W6wZYK= Mn\3NlUyOjNyOEK=
Eca109 MoKwSpVv[3Srb36gRZN{[Xl? NYLzTmxVOC53wrFOwG0> NGm0c5o3NzF{L{K0JIg> MnPve4F1\XJ? NEjEUXVqdmirYnn0d{Bk\WyuIH3p[5JifGmxbtMg NX7pdXdpOjVzMkOwPFI>
Eca109 MXjGeY5kfGmxbjDBd5NigQ>? MWGwMlXDqM7:TR?= NEDjfVgzPCCq NVXodXhwf2G2ZYK= NXX0SpF1cW6qaXLpeJMh[2WubDDpcpZie2mxbh?= M4f2Z|I2OTJ|MEiy
Eca109 M1nm[Wdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M4q5dVAvPcLizszN NWf0dmpYOjRiaB?= NF\5VZh4[XSnch?= MkLlbY5lfWOnczDHNk9OKGG{cnXzeEBqdiC2aHWgZ4VtdCCleXPs[S=> NWnCe5c6OjVzMkOwPFI>
Eca109 M334fWZ2dmO2aX;uJGF{e2G7 MUmwMlUwOSEQvF2= NW\zfXU1OjRiaB?= MnLOe4F1\XJ? MVXk[YNz\WG|ZYOg[ZhxemW|c3nvckBw\iCQRj5OvmIzKGGwZDDNUXAz M{HRb|I2OTJ|MEiy
SW1116  NGDkclVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MmnwNE42NzFxMj:1JO69VQ>? MXS0PEBp M{LETGROW09? MoXx[Y5p[W6lZYOgeIhmKEenZnn0bY5q[iCrbnT1Z4VlKGOnbHygbY5pcWKrdHnvci=> MWOyOFg4PDJ6Nh?=
LOVO NX62PY02T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NEL6e20xNjVxMT:yM|Uh|ryP MonuOFghcA>? NVzs[|R4TE2VTx?= MnjP[Y5p[W6lZYOgeIhmKEenZnn0bY5q[iCrbnT1Z4VlKGOnbHygbY5pcWKrdHnvci=> NYP6elJSOjR6N{SyPFY>
SW1116  NGXHbFJHfW6ldHnvckBCe3OjeR?= NUTNR5J3OTBizszN M4j6U|Q5KGh? M{n5bWROW09? NYrmOWVrcW6lcnXhd4V{KHSqZTDl[oZm[3SrdnWgZZQhcW6qaXLpeIlv\yCDS2SgZY5lKG2WT2Kgd4lodmGuaX7nJJBifGi5YYnzJINwdWKrbnXkJJdqfGhiZ3XmbZRqdmmk NVjyfGZJOjR6N{SyPFY>
LOVO NIn4XZlHfW6ldHnvckBCe3OjeR?= NH;w[WYyOCEQvF2= Mlj3OFghcA>? Ml6wSG1UVw>? MUnpcoNz\WG|ZYOgeIhmKGWoZnXjeIl3\SCjdDDpcohq[mm2aX7nJGFMXCCjbnSgcXRQWiC|aXfuZYxqdmdicHH0bJdigXNiY3;tZolv\WRid3n0bEBo\W[rdHnubYI> NEXaWmIzPDh5NEK4Oi=>
SW1116  MnHJRZBweHSxc3nzJGF{e2G7 M2nsVVExKM7:TR?= MWK0PEBp MYPEUXNQ NITzZ4FmdmijbnPld{BI\W[rdHnubYIucW6mdXPl[EBieG:ydH;zbZM> MYCyOFg4PDJ6Nh?=
LOVO M2TOcWFxd3C2b4Ppd{BCe3OjeR?= NIm5eYYyOCEQvF2= MWO0PEBp MkjkSG1UVw>? NH3iUolmdmijbnPld{BI\W[rdHnubYIucW6mdXPl[EBieG:ydH;zbZM> NX7GfJZsOjR6N{SyPFY>
RPMI-8226 M1i4V2Fxd3C2b4Ppd{BCe3OjeR?= NHjLSIsyNzJizszN MmHTOFgwPzJxOU[gbC=> MkPYSG1UVw>? NYTBfnlEcW6mdXPld{Bk\WyuIHHwc5B1d3Orcx?= MVKyOFg{OzFyOB?=
OPM-2  NHTwXZlCeG:ydH;zbZMhSXO|YYm= MYmxM|Ih|ryP MnThO|IwQTZxMUKwJIg> MnTKSG1UVw>? NF7Ud2RqdmS3Y3XzJINmdGxiYYDvdJRwe2m| NYnuWWNzOjR6M{OxNFg>
JJN3  MWLBdI9xfG:|aYOgRZN{[Xl? NXrVc2VnOC53L{Gg{txO MYiyOE81QCCq MWXEUXNQ NIO0VpZqdmS3Y3XzJINmdGxiYYDvdJRwe2m| NF7ITIszPDh|M{GwPC=>
NCI-H929  MX;BdI9xfG:|aYOgRZN{[Xl? MkW3NU8zKM7:TR?= MoewO|IwQTZxMUKwJIg> M1nqTGROW09? M1G1[Ilv\HWlZYOgZ4VtdCCjcH;weI9{cXN? MlPXNlQ5OzNzMEi=
RPMI-8226 MV\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Mln6NU8zKM7:TR?= MV:yOE81QC95MjDo M3rnVWROW09? NVf2OllG[W[oZXP0d{Bk\WyuIHP5Z4xmKHC{b3fy[ZN{cW:wIH7l[4F1cX[nbIm= NWT6U|BEOjR6M{OxNFg>
OPM-2  M{G1e2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MorMNU8zKM7:TR?= MofNNlQwPDhxN{KgbC=> MYnEUXNQ MYnh[oZm[3S|IHPlcIwh[3mlbHWgdJJw\3Knc4Ppc44hdmWpYYTpeoVtgQ>? MY[yOFg{OzFyOB?=
JJN3  MonGS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NGXzN2IxNjVxMTFOwG0> NWD5U49tOjRxNEivO|IhcA>? MUnEUXNQ M3e1ToFn\mWldIOgZ4VtdCCleXPs[UBxem:pcnXzd4lwdiCwZXfheIl3\Wy7 MUGyOFg{OzFyOB?=
NCI-H929  NYDlcop7T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M4q5RlEwOiEQvF2= M4XhN|I1NzR6L{eyJIg> MXzEUXNQ MX\h[oZm[3S|IHPlcIwh[3mlbHWgdJJw\3Knc4Ppc44hdmWpYYTpeoVtgQ>? MVWyOFg{OzFyOB?=
HeLa NH3wWlZMcW6jc3WgRZN{[Xl? M2nxPWtqRTFyMEFihLM2ODByIN88UUBnd3JiaFXOWFE> MlLENlQ4QDByOUi=
HeLa M37BPWtqdmG|ZTDBd5NigQ>? MVvLbV02NjZiwsGgNE42KM7:TTDmc5IhcEWQVEK= MnPLNlQ4QDByOUi=
HeLa NH6w[oRMcW6jc3WgRZN{[Xl? NGn4cGJMcT1{MT62JOKyKDNwMDFOwG0h\m:{IHjDUnQy M17Dd|I1PzhyMEm4
HeLa MWXLbY5ie2ViQYPzZZk> MYjLbV0yPC52INMxJFQvPiEQvF2g[o9zKGiFTmSz MXeyOFc5ODB7OB?=
NB4 Mk[3SpVv[3Srb36gRZN{[Xl? MWKyMlUwPS95LkWvNVAh|ryP NUfM[oRoOjRiaB?= M4THZ2ROW09? MVzpcoNz\WG|ZXGgeIhmKGW6cILld5Nqd25ib3[gdJJm[3W{c3;yJI1qWi1zMkXh MVOyOFQ5PDh5MB?=
CD4+ CD25− T  NYLiW5hvTnWwY4Tpc44hSXO|YYm= M3O1T|EwPSEQvF2= MmDTdoVlfWOnUzDncI9j[WxiRF7BJI1mfGi7bHH0bY9v NGTlNFQzPDR5NkO2NC=>
BV-173 MYnBdI9xfG:|aYOgRZN{[Xl? M33tR|AvOjVxMD61M|AvPzVxMTFOwG0> NXrYVJh6PDhxN{KvPVYhcA>? NIXG[|bDqFCEUx?= NGj2RpdqdmS3Y3XzJINmdGxiYYDvdJRwe2m|IHnuJIJwfGhiZH;z[U0h[W6mIITpcYUuKGSncHXu[IVvfCCvYX7u[ZI> NGrreGIzPDR{M{[xNy=>
ML-1 M32yUmFxd3C2b4Ppd{BCe3OjeR?= NUfwb2liOC5{NT:wMlUwOC55NT:xJO69VQ>? MoTSOFgwPzJxOU[gbC=> NFfsWZLDqFCEUx?= MWHpcoR2[2W|IHPlcIwh[XCxcITvd4l{KGmwIHLveIgh\G:|ZT2gZY5lKHSrbXWtJIRmeGWwZHXueEBu[W6wZYK= M{i1W|I1PDJ|NkGz
HL-60 MXnBdI9xfG:|aYOgRZN{[Xl? Ml;6NE4zPS9yLkWvNE44PS9zIN88US=> NIP2UGs1QC95Mj:5OkBp MUVCpHBDWw>? M{fvZ4lv\HWlZYOgZ4VtdCCjcH;weI9{cXNiaX6gZo91cCCmb4PlMUBidmRidHnt[U0h\GWyZX7k[Y51KG2jbn7ldi=> MUeyOFQzOzZzMx?=
KG-1a NYXaXZYySXCxcITvd4l{KEG|c3H5 NF3WZYQxNjJ3L{CuOU8xNjd3L{Gg{txO Moq0OFgwPzJxOU[gbC=> NV7lO5l2yqCSQmO= MlG3bY5lfWOnczDj[YxtKGGyb4D0c5NqeyCrbjDic5RpKGSxc3WtJIFv\CC2aX3lMUBl\XCnbnTlcpQhdWGwbnXy NX7XZlhJOjR2MkO2NVM>
BV-173 NVjqS3BHTnWwY4Tpc44hSXO|YYm= NYPl[YxCOjVyL{WwNI5O MUC0PEBp M3TVSeKhWEKV MYTpcoR2[2W|IHTlcIF6\WRiYX7kJJN2e3SjaX7l[EBTV1NiaX7jdoVie2V? M{\nNlI1PDJ|NkGz
CEM MkfrSpVv[3Srb36gRZN{[Xl? M1KwSlI2OC93MEDuUS=> NX;tdlU2PDhiaB?= MnvRxsBRSlN? M2G2[Ilv\HWlZYOg[IVt[XmnZDDhcoQhe3W|dHHpcoVlKFKRUzDpcoNz\WG|ZR?= Mn3wNlQ1OjN4MUO=
HL-60 MoHTSpVv[3Srb36gRZN{[Xl? Ml3FNlUxNzVyMH7N M3\V[FQ5KGh? NECwSGTDqFCEUx?= MlTTbY5lfWOnczDk[YxigWWmIHHu[EB{fXO2YXnu[YQhWk:VIHnuZ5Jm[XOn MW[yOFQzOzZzMx?=
ML-1 NIPSNplHfW6ldHnvckBCe3OjeR?= MWeyOVAwPTBybl2= M{XYc|Q5KGh? NVX2T|RjyqCSQmO= M{XZeolv\HWlZYOg[IVt[XmnZDDhcoQhe3W|dHHpcoVlKFKRUzDpcoNz\WG|ZR?= NGPMOZIzPDR{M{[xNy=>
DLD-1 M37sSGZ2dmO2aX;uJGF{e2G7 M4ToO|I2OC93MEDuUS=> MXu0PEBp NYXs[JFUyqCSQmO= M{HnN4RwKG6xdDDpcoR2[2W|IHTlcIF6\WRiYX7kJJN2e3SjaX7l[EBTV1NiaX7jdoVie2V? MkjaNlQ1OjN4MUO=
HCT-116 M33DUWZ2dmO2aX;uJGF{e2G7 M3f0TlI2OC93MEDuUS=> M2TJV|Q5KGh? NInmUFnDqFCEUx?= NXSz[Jc1\G9ibn;0JIlv\HWlZYOg[IVt[XmnZDDhcoQhe3W|dHHpcoVlKFKRUzDpcoNz\WG|ZR?= NXfLNGFJOjR2MkO2NVM>
U937-A/E-9/14/18  M{DRfGFxd3C2b4Ppd{BCe3OjeR?= NXrxU|IyOC5yMT:wMlEwOS9zMDFOwG0> MVO0PEBp NGPNVm1qdmS3Y3XzJINmdGxiYYDvdJRwe2m|IHnuJIEh\G:|ZT3k[ZBmdmSnboSgcYFvdmW{ NU\wdm44OjR|MEC0OVY>
HT29 MULHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M3HhV|czKGh? NHzOZnRKSzVyPUG0NFDDuTF5OTFOwG0> NEG0UZIzPDF5MkC2NS=>
SW48 MX7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M1LVPFczKGh? MYfJR|UxRTF3LkNCtVYvOiEQvF2= MVOyOFE4OjB4MR?=
HCT116 MYLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MUm3NkBp MnrITWM2OD1zLkhCtVAvPCEQvF2= NIG5dnAzPDF5MkC2NS=>
HepG2 MnrBSpVv[3Srb36gRZN{[Xl? Mnj5NE42NzFizszN NHLJU4YzPCCq MYPEUXNQ NUPKVIJxfXBvcnXneYxifGWmIITo[UBz\WyjdHn2[UBQS1SQMjDtVm5CKGGwZDDwdo91\WmwIHX4dJJme3Orb36= NXPzV3BbOjRzNE[4O|Q>
LS174T MWHGeY5kfGmxbjDBd5NigQ>? NIqwVmsxNjVxMTFOwG0> NGrONJEzPCCq M{fqWGROW09? NEHYeWxt\WGmIITvJIFvKGmwY4LlZZNmKG:oIF;DWG4zKGyndnXsdy=> NX\VTHpIOjRzNE[4O|Q>
HepG2 NVXsZpdnSXCxcITvd4l{KEG|c3H5 NYO4V3lSOS9zMD:xNFAh|ryP MlnKO{Bl M{HVXmROW09? MWXpcoR2[2W|IHPlcIwh[XCxcITvd4l{KGmwIHGg[I9{\S2mZYDlcoRmdnRibXHucoVz MkXnNlQyPDZ6N{S=
LS174T NIe1b5FCeG:ydH;zbZMhSXO|YYm= MYixM|ExNzFyMDFOwG0> M2XQZ|ch\A>? M3fDTGROW09? MnPnbY5lfWOnczDj[YxtKGGyb4D0c5NqeyCrbjDhJIRwe2VvZHXw[Y5l\W62IH3hco5meg>? MYCyOFE1Pjh5NB?=
QBC-939 NFzYWotCeG:ydH;zbZMhSXO|YYm= NFvxXlgyNzFyL{GwNEDPxE1? Mmj3O{Bl MYTEUXNQ NYXvT2FXcW6mdXPld{Bk\WyuIHHwc5B1d3OrczDpckBiKGSxc3Wt[IVx\W6mZX70JI1idm6nch?= NX3BVlA4OjRzNE[4O|Q>
U251 M2r6U2Fxd3C2b4Ppd{BCe3OjeR?= MXmxM|ExNzFyMDFOwG0> Mn;TO{Bl NFvQS4pFVVOR NVrn[2tYcW6mdXPld{Bk\WyuIHHwc5B1d3OrczDpckBiKGSxc3Wt[IVx\W6mZX70JI1idm6nch?= NVHqe3pCOjRzNE[4O|Q>
HL-60 NV3UOG1YT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MV6xJO69VQ>? M2TDUlQ5KGh? Mnq3bY5kemWjc3XzJGczNXCqYYPlJINmdGxiZoLhZ5Rqd25? Mm\BNlQxODB|MkS=
MDA‑MB‑453 NFyyRlJHfW6ldHnvckBCe3OjeR?= NUTscnhsOC5{L{Gg{txO MUO3NkBp NEn1TlVk[XW|ZYOgdoUu\XiycnXzd4lwdiCxZjDjcIF2\GmwwrCxxsA> NHPVWFMzOzh2NEKyPC=>
HCC1569 NGK5V|dHfW6ldHnvckBCe3OjeR?= NHrMcmgxNjJxMTFOwG0> NXPGTot1PzJiaB?= NHewPWRk[XW|ZYOgdoUu\XiycnXzd4lwdiCxZjDjcIF2\GmwwrCxxsA> NGLRSnYzOzh2NEKyPC=>
BT‑474 NXHkdXdZTnWwY4Tpc44hSXO|YYm= M1XoRlAvOi9zIN88US=> MmjzO|IhcA>? M4fKOoNifXOnczDy[U1mgHC{ZYPzbY9vKG:oIHPsZZVlcW8EoEJCpC=> M2q5fVI{QDR2MkK4
AGS MX7BdI9xfG:|aYOgRZN{[Xl? MXm1M|ExNzJyL{WwJO69VQ>? NWLXcJo3PDkEoHlCpC=> NXTORnhDTE2VTx?= MkDGbY5pcWKrdIOgeIhmKGOnbHygeoli[mmuaYT5xsA> MV:yN|U5Ojd6NB?=
A549 M4PrUWFxd3C2b4Ppd{BCe3OjeR?= NWLueVFNPS9zMD:yNE82OCEQvF2= M1nvU|Q5yqCqwrC= MYnEUXNQ M3LFTYlvcGmkaYTzJJRp\SClZXzsJJZq[WKrbHn0feKh M2XoeFI{PTh{N{i0
AGS  MYnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M1jvZlUwOTBxMkCvOVAh|ryP MY[0POKhcMLi NVPhWJVxTE2VTx?= NIDyeWRqdmS3Y3XzJGczN01icHjhd4Uh[XK{ZYP0xsA> M3HXbVI{PTh{N{i0
Kasumi-1 M1zpe2Fxd3C2b4Ppd{BCe3OjeR?= MnzKNE42KM7:TR?= MYe0POKhcMLi MlT0[IVkemWjc3XzJJRp\SClZXzsJJZq[WKrbHn0fUBkdy22cnXheIVlKHerdHigWIYuVlBvc3O= M4raZlI{PDl|M{S4
OCI-AML3 NX;CO25ZSXCxcITvd4l{KEG|c3H5 M{fPSlIvPSEQvF2= NUjHcWlRPDkEoHlCpC=> M{LC[4Rm[3KnYYPld{B1cGViY3XscEB3cWGkaXzpeJkh[29vdILlZZRm\CC5aYToJHRnNU6SLYPj NYDqcnlSOjN2OUOzOFg>
MV4-11 MoXPRZBweHSxc3nzJGF{e2G7 M4i3RlIvPSEQvF2= M4\EelQ5yqCqwrC= MUjk[YNz\WG|ZYOgeIhmKGOnbHygeoli[mmuaYT5JINwNXS{ZXH0[YQhf2m2aDDU[k1PWC2|Yx?= MWeyN|Q6OzN2OB?=
NK  MXHDfZRwfG:6aYT5JGF{e2G7 NHiwUG4xNjB{LUKwJO69VQ>? NV;2V2p3PSCm MYrk[YNz\WG|ZYOgeIhmKGO7dH;sfZRq[yCjY4Tpeol1gSCxZjDOT{Bk\WyuczDheEBqdnSncn3l[IlifGViY3;uZ4VvfHKjdHnvcpMhemW|dXz0bY5oKGmwIHGgWU1{cGGyZXSg[I9{\eLCk4Lld5BwdnOnIHP1dpZm NWq5RnhyOjN|MkiwPFg>
NK  MX\BdI9xfG:|aYOgRZN{[Xl? NVPp[ZpWOC5yMj2yNEDPxE1? M3PqOVUh\A>? Mnmx[IVkemWjc3WgUmsh[2WubDDwdo9tcW[ncnH0bY9vKGGwZDD2bYFjcWyrdImgZZMhfGinIHPvcoNmdnS{YYTpc44hcW6lcnXhd4Vl MmD1NlM{OjhyOEi=
NK  NF\kOHdHfW6ldHnvckBCe3OjeR?= MnPlNE4xOS1{MDFOwG0> NIPmVWw2KGR? NITwU|Nk[XW|ZYOgbJlxd22ndHj5cIF1cW:wIH;mJG5MKGOnbHzzJIlvKGFiZH;z[gKBm3Knc4DvcpNm MomyNlM{OjhyOEi=
MOLT4/DNR MluwSpVv[3Srb36gRZN{[Xl? MoXoOUDPxE1? MVi0JIQ> NHzHd4Nz\WS3Y3XzJGFDS0JzIH3SUmEh\XiycnXzd4lwdg>? Mn;JNlMxPjB3N{C=
Jurkat/DOX MnjtSpVv[3Srb36gRZN{[Xl? NYTDN3QzPSEQvF2= M{LWd|Qh\A>? MUfy[YR2[2W|IFHCR2IyKG2UTlGg[ZhxemW|c3nvci=> NXT2PZhiOjNyNkC1O|A>
MOLT4/DNR MoTlS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M{nTSlUh|ryP M4DWPFQh\A>? MV3y[YR2[2W|IITo[UBKSzVywrD2ZYx2\SCob4Kg[IF2dm:{dXLpZ4lvKHOnboPpeIl3cXS7 NGrkcGYzOzB4MEW3NC=>
Jurkat/DOX MVPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MoraOUDPxE1? NWf0U5NuPCCm MWTy[YR2[2W|IITo[UBKSzVywrD2ZYx2\SCob4Kg[IF2dm:{dXLpZ4lvKHOnboPpeIl3cXS7 NXy1S2dMOjNyNkC1O|A>
ccRCC  NH7JUHNCeG:ydH;zbZMhSXO|YYm= M4fxc|AvODFvMUFOwG0> NVL1NJRjPzJiaB?= NXPoTYJiTE2VTx?= NYDWc|RIcGG|IH3pcolu[WxiZX\m[YN1KG:wIHPlcIwheHKxbHnm[ZJifGmxbh?= MXOyNlgzPjR4Nx?=
TNBC  MXzBdI9xfG:|aYOgRZN{[Xl? M1XOTVAvODFvMUFOwG0> MVu3NkBp NFXBbIFFVVOR M1;NZYhieyCvaX7pcYFtKGWoZnXjeEBwdiClZXzsJJBzd2yrZnXyZZRqd25? M1fHWlIzQDJ4NE[3
A498 MYPBdI9xfG:|aYOgRZN{[Xl? MYKwMlAyNTFyzszN MYe3NkBp Mk[3SG1UVw>? NIn6U2hqdmS3Y3XzJJN6dmW{Z3nzeIlkKHKnc4DvcpNme8Lid3n0bEBzd22rZHXwd4lv M2W5d|IzQDJ4NE[3
KIJ265T NHvWSWdCeG:ydH;zbZMhSXO|YYm= MWOwMlAyNTFyzszN NV34clhLPzJiaB?= Mo\nSG1UVw>? M2jabolv\HWlZYOgd5lv\XKpaYP0bYMhemW|cH;ud4V{yqC5aYToJJJwdWmmZYDzbY4> NUHocFREOjJ6Mk[0Olc>
MDA-231 MlvqRZBweHSxc3nzJGF{e2G7 MoTQNE4xOS1zMN88US=> MlfTO|IhcA>? Mk\hSG1UVw>? MmnVbY5lfWOnczDzfY5memerc4TpZ{Bz\XOyb37z[ZPDqHerdHigdo9ucWSncIPpci=> MViyNlgzPjR4Nx?=
BT-20 NFHsfYZCeG:ydH;zbZMhSXO|YYm= MoTlNE4xOS1zMN88US=> Mm[xO|IhcA>? MljFSG1UVw>? NHX2c2tqdmS3Y3XzJJN6dmW{Z3nzeIlkKHKnc4DvcpNme8Lid3n0bEBzd22rZHXwd4lv MWeyNlgzPjR4Nx?=
U937 MlzXS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MkD4OU0zOCEQvF2= M33nSlI1NzR6L{eyJIg> MX\pcoR2[2W|IHGg[IVkemWjc3WgbY4h[2WubDD2bYFjcWyrdImgbY4h[SClb37j[Y51emG2aX;uMUBidmRidHnt[U1l\XCnbnTlcpQhdWGwbnXy MV:yNlc3PzB{MR?=
HL60 MX\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MkLYOU0zOCEQvF2= NIC3UZMzPC92OD:3NkBp NGrWdXlqdmS3Y3XzJIEh\GWlcnXhd4UhcW5iY3XscEB3cWGkaXzpeJkhcW5iYTDjc45k\W62cnH0bY9vNSCjbnSgeIlu\S2mZYDlcoRmdnRibXHucoVz NWrxbFR2OjJ5NkewNlE>
U937 Ml7xRZBweHSxc3nzJGF{e2G7 M33oNlE2KM7:TR?= M1fTNlI1NzR6L{eyJIg> NGXIW5dqdmS3Y3XzJINmdGxiYYDvdJRwe2m| NECy[JAzOjd4N{CyNS=>
HL60 M1\V[mFxd3C2b4Ppd{BCe3OjeR?= MVuxOUDPxE1? NVzTRY91OjRxNEivO|IhcA>? Mo\IbY5lfWOnczDj[YxtKGGyb4D0c5Nqew>? NF3ifmwzOjd4N{CyNS=>
LS411N  MYXBdI9xfG:|aYOgRZN{[Xl? MUSwMlUh|ryP MlnOO|IhcA>? NUXlVmg{cW6lcnXhd4V{KE[jczDtVm5CKGyndnXs MWGyNlQ3OTZ7NR?=
MDA-MB-231 M1\o[mFxd3C2b4Ppd{BCe3OjeR?= M{XsfFExKM7:TR?= NUHFPFlQPDhiaB?= MVry[YR2[2W|IHPlcIwhfmmjYnnsbZR6KGmwIHGg[I9{\S2mZYDlcoRmdnRibXHucoVz NUDkWY83OjF6OEe2PVc>
MCF-7  M{\jO2Fxd3C2b4Ppd{BCe3OjeR?= NW\mRmhUOTBizszN NF3kWoY1QCCq M4H5O5Jm\HWlZYOgZ4VtdCC4aXHibYxqfHliaX6gZUBld3OnLXTldIVv\GWwdDDtZY5v\XJ? MmXGNlE5QDd4OUe=
A375 MkXES5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MnrnNE42KM7:TR?= NVn3RYxvOS93L{ig[C=> Mn3rbY5pcWKrdIOgdJJwdGmoZYLheIlwdiCjbnSgbY5lfWOnczDkbYZn\XKnboTpZZRqd25ib3[gcYVt[W6xbXGgZ4VtdHN? M2PPdlIyPzl4NkKy
SKMEL1 MYDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MYSwMlUh|ryP M2\XTVEwPS96IHS= MlHwbY5pcWKrdIOgdJJwdGmoZYLheIlwdiCjbnSgbY5lfWOnczDkbYZn\XKnboTpZZRqd25ib3[gcYVt[W6xbXGgZ4VtdHN? NHXVZ3gzOTd7Nk[yNi=>
SKMEL3 MnfDS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M{O5bFAvPSEQvF2= MV:xM|UwQCCm NWjzSXQ5cW6qaXLpeJMheHKxbHnm[ZJifGmxbjDhcoQhcW6mdXPld{BlcW[oZYLlcpRq[XSrb36gc4YhdWWuYX7vcYEh[2WubIO= MkHCNlE4QTZ4MkK=
SKMEL28 MUXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M3z6PFAvPSEQvF2= M4PDV|EwPS96IHS= MmKwbY5pcWKrdIOgdJJwdGmoZYLheIlwdiCjbnSgbY5lfWOnczDkbYZn\XKnboTpZZRqd25ib3[gcYVt[W6xbXGgZ4VtdHN? M{jhdFIyPzl4NkKy
MeWo MVXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M1\Cd|AvPSEQvF2= MYCxM|UwQCCm NV3DPVZzcW6qaXLpeJMheHKxbHnm[ZJifGmxbjDhcoQhcW6mdXPld{BlcW[oZYLlcpRq[XSrb36gc4YhdWWuYX7vcYEh[2WubIO= NHLwS4EzOTd7Nk[yNi=>
B16 NXP4[JliT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MVGwMlUh|ryP NXTvTnJxOS93L{ig[C=> NFfPT2FqdmirYnn0d{Bxem:uaX\ldoF1cW:wIHHu[EBqdmS3Y3XzJIRq\m[ncnXueIlifGmxbjDv[kBu\Wyjbn;tZUBk\Wyucx?= NGDIZnkzOTd7Nk[yNi=>
Ly 1 NF3TelVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NHO5VYczPCCq NXTiOoU6UUN3ME23MlMh|ryP MUGyNVc4OjB2OR?=
Ly 7 NVrNS20xT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M{Ho[FI1KGh? NHq4WHNKSzVyPUGwMlch|ryP M1fKW|IyPzd{MES5
Su-DHL6 MVTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NImwTpkzPCCq NE\HbXBKSzVy78{eNlAh|ryP M33NTVIyPzd{MES5
Ly 10 MVjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NVH2bmt6OjRiaB?= NETiZldKSzVy78{eNlAh|ryP M4nue|IyPzd{MES5
RIVA NYnnc3pVT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NHvP[VEzPCCq MkDPTWM2OO,:nkKwJO69VQ>? NFHablgzOTd5MkC0PS=>
Su-DHL2 NH31RmpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NXfKOpIzOjRiaB?= M{PnVmlEPTExvK6yNEDPxE1? NInCcnkzOTd5MkC0PS=>
Ly 1 Mn;MS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M3niUFQ5KGh? NYTVVFdPUUN3ME2wMlM1KM7:TR?= Mn\MNlE4PzJyNEm=
Ly 7 NWfObJN6T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MUK0PEBp MXHJR|UxRTBwMEK1JO69VQ>? MoDBNlE4PzJyNEm=
Su-DHL6 NIq4XIVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MnPiOFghcA>? MlqwTWM2OO,:nkKwJO69VQ>? MmLhNlE4PzJyNEm=
Ly 10 M2HZeWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NVzC[lJrPDhiaB?= NFTQTnZKSzVyPUGuPEDPxE1? MnL6NlE4PzJyNEm=
RIVA MWXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MXu0PEBp NGjlS3lKSzVy78{eNlAh|ryP NW\iUmEyOjF5N{KwOFk>
Su-DHL2 M13kRmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NGP1XJc1QCCq MXXJR|UxRTF5LkSg{txO NXjTNphTOjF5N{KwOFk>
Ly 1 MnzlS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NYDTTIRXPzJiaB?= MnLvTWM2OD1yLkCxJO69VQ>? MoTMNlE4PzJyNEm=
Ly 7 M4ezd2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NXLUfYVuPzJiaB?= MnfnTWM2OD1yLkCxPEDPxE1? M2XOS|IyPzd{MES5
Su-DHL6 M1LxV2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M3LCWVczKGh? MlH5TWM2OD1zLk[g{txO NGH0OoMzOTd5MkC0PS=>
Ly 10 NE[5NnVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MY[3NkBp MUHJR|UxRTFwMjFOwG0> MlO3NlE4PzJyNEm=
RIVA M3TTfmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NE[xOpA4OiCq NWq2N5FzUUN3MP-8olIxKM7:TR?= NUXjdYZxOjF5N{KwOFk>
Su-DHL2 NV\ldIZlT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NUT5c5VTPzJiaB?= NIXid2RKSzVyPUGxMlIh|ryP MV2yNVc4OjB2OR?=

他の多くの細胞株試験データをご覧になる場合はこちらをクリックして下さい

アッセイ
Methods Test Index PMID
Western blot
Survivin / Bcl-2 / p53 / c-Myc / DNMT1; 

PubMed: 26384351     


HL60/ADR and kasumi-1 cells were lysed after treated with 0, 1, 2, 4μM decitabine for 72h, and antibodies against β-actin was used as loading control of whole cell proteins in western blotting. The expression of DNMT1, c-Myc, P53, Bcl-2 and Survivin were determined in AML cells.

p-AKT / AKT / p-GSK3β / GSK3β / p-Myc / Myc / p-P70 / P70 / p-4EBP-1 / 4EBP-1 / PTEN; 

PubMed: 25762617     


Effects of decitabine on the expression of survival pathway proteins at the indicated concentrations.

phospho-p38 / p38 / phospho-NFκB / NFκB; 

PubMed: 26617834     


Decitabine suppressed the phosphorylation of p38 and NF-κB.

p-JAK1 / JAK1 / p-JAK2 / JAK2 / p-STAT3 / STAT3 ; 

PubMed: 26692933     


DAC inhibits the activity of JAK/STAT3 signaling pathway in HL-60 cells. A. HL-60 cells were exposed to 0.2-1.0 μM DAC for 48 h. Cell lysates were prepared and subjected to western blot assay for p-STAT3 (Tyr705 and Ser727) and total STAT3 protein. DAC treatment led to the dephosphorylation of STAT3 both at Tyr705 and Ser727, with moderate effect on total STAT3 protein. B. DAC also down-regulated the expression of p-JAK1 and p-JAK2 as well as total JAK1 and JAK2 in HL-60 cells. The protein expression of STAT3 and JAKs was normalized to that of β-actin and results are representative from three independent experiments.

E-cadherin / N-cadherin / Snail / MMP-2 / MMP-9 / Bcl-2 / Bax; 

PubMed: 28152502     


The protein level of EMT and invasion related proteins E-cadherin, N-cadherin, Snail, MMP-2, MMP-9 and the protein level of the apoptotic-related proteins, BCL-2 and Bax were detected by western blot. β-actin served as a internal control.

26384351 25762617 26617834 26692933 28152502
Immunofluorescence
DNMT1; 

PubMed: 21303982     


Ren-01 cells (low passage number RCC cells) at <40% confluence were treated with decitabine 0.5 μM. DNMT1 was quantified 48 hours later by immuno-fluorescence (green dots). DAPI was used to stain nuclei (blue stain).

E-cadherin / MMP-9; 

PubMed: 28152502     


Immunofluorescence microscopy to identify invasion-promoting molecule MMP-9 and EMT-protective molecule E-cadherin in YES-2 and TE13 cells treated with DAC. 

21303982 28152502
Growth inhibition assay
Cell viability; 

PubMed: 26384351     


Cells were treated with Decitabine for 72 h. Viability was measured by MTT assay in AML cells and patient samples Different AML cells.

26384351
体内試験 In a ALK+ KARPAS-299 murine xenograft model, Decitabine at a dose of 2.5 mg/kg causes increased apoptosis and reduced proliferation of tumor cells, and also results in demethylation of tumor suppressor p16INK4A. [2]

お薦めの試験操作(参考用のみ)

キナーゼ試験:[1]
+ 展開

DNA synthesis assay :

The rate of DNA synthesis is measured by the incorporation of radioactive thymidine into DNA. HL-60 and KG1a cells are suspended in 2 mL RPMI medium containing 10% fetal serum in 6-well (35 mm diameter) dishes and incubated with different concentrations of corresponding drugs for 48 hours (drugs are added simultaneously). At 48 hours, 0.5 μCi [3H] thymidine (6.7 Ci/mmol) is added to each well and incubated for an additional 24 hours. The cells are placed on GF/C glass fiber filters (2.4 cm diameter), washed with cold 0.9% NaCl, 5% cold trichloroacetic acid and ethanol. The filters containing the DNA are then dried, placed in EcoLite scintillation liquid (ICN) and the radioactivity measured using Beckman LS 6000IC scintillation counter. The IC50 is defined as the concentration of drug that inhibits 50% of the DNA synthesis of the leukemic cell lines from the dose–response curve.
細胞試験: [1]
+ 展開
  • 細胞株: HL-60 and KG1a
  • 濃度: 0-500 nM
  • 反応時間: 96 hours
  • 実験の流れ: For the growth inhibition assay, cells in log phase are placed in 5 mL of medium. Different concentrations of Decitabine are added to the medium simultaneously. Cell counts are performed at the indicated times using a model ZM Coulter Counter. The concentration that produces 50% inhibition of growth (IC50) is determined from the growth curves of the drug treated leukemic cell lines.
    (参考用のみ)
動物試験:[2]
+ 展開
  • 動物モデル: KARPAS-299 human cells are inoculated subcutaneously into the right and left flanks of the mice.
  • 製剤: Decitabine is dissolved in sterile PBS .
  • 投薬量: ≤2.5 mg/kg
  • 投与方法: Administered via i.p.
    (参考用のみ)

溶解度 (25°C)

体外 DMSO 45 mg/mL (197.18 mM)
Water 10 mg/mL (43.81 mM)
Ethanol Insoluble
体内 左から(NMPから)右の順に溶剤を製品に加えます(文献ではなく、Selleckの実験によるデータ):
water
混合させたのち直ちに使用することを推奨します。
10mg/mL

* 溶解度測定はSelleck技術部門によって行われており、その他文献に示されている溶解度と差異がある可能性がありますが、同一ロットの生産工程で起きる正常な現象ですからご安心ください。

化学情報

分子量 228.21
化学式

C8H12N4O4

CAS No. 2353-33-5
保管
in solvent
別名 Deoxycytidine

便利ツール

モル濃度計算器

モル濃度計算器

求めたい質量、体積または濃度を計算してください。

質量 (g) = 濃度 (mol/L) x 体積 (L) x 分子量 (g/mol)

モル濃度計算器方程式

  • 質量
    濃度
    体積
    分子量

*貯蔵液を準備するとき、常に、オンであるとわかる製品のバッチに特有の分子量を使って、を通してラベルとMSDS/COA(製品ページで利用可能な)。

希釈計算器

希釈計算器

貯蔵液を準備するために必要な希釈率を計算してください。Selleck希釈計算器は、以下の方程式に基づきます:

開始濃度 x 開始体積 = 最終濃度 x 最終体積

希釈の計算式

この方程式は、一般に略語を使われます:C1V1 = C2V2 ( 入力 出力 )

  • C1
    V1
    C2
    V2

常に貯蔵液を準備するとき、小びんラベルとMSDS/COA(オンラインで利用できる)で見つかる製品のバッチに特有の分子量を使ってください。

連続希釈計算器方程式

  • 連続希釈剤

  • 計算結果

  • C1=C0/X C1: LOG(C1):
    C2=C1/X C2: LOG(C2):
    C3=C2/X C3: LOG(C3):
    C4=C3/X C4: LOG(C4):
    C5=C4/X C5: LOG(C5):
    C6=C5/X C6: LOG(C6):
    C7=C6/X C7: LOG(C7):
    C8=C7/X C8: LOG(C8):
分子量計算器

分子量计算器

そのモル質量と元素組成を計算するために、合成物の化学式を入力してください:

総分子量:g/mol

チップス: 化学式は大文字と小文字の区別ができます。C10H16N2O2 c10h16n2o2

モル濃度計算器

質量 濃度 体積 分子量

臨床試験

NCT Number Recruitment Conditions Sponsor/Collaborators Start Date Phases
NCT03828084 Not yet recruiting Healthy EpiDestiny Inc. April 3 2019 Phase 1
NCT03828084 Not yet recruiting Healthy EpiDestiny Inc. April 3 2019 Phase 1
NCT03844815 Not yet recruiting Acute Myeloid Leukemia University of Chicago|AbbVie April 10 2019 Phase 1
NCT03844815 Not yet recruiting Acute Myeloid Leukemia University of Chicago|AbbVie April 10 2019 Phase 1
NCT03875287 Not yet recruiting Solid Tumor Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins|Astex Pharmaceuticals March 2019 Phase 1
NCT03875287 Not yet recruiting Solid Tumor Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins|Astex Pharmaceuticals March 2019 Phase 1

技術サポート

ストックの作り方、阻害剤の保管方法、細胞実験や動物実験の際に注意すべき点など、製品を取扱う時に問い合わせが多かった質問に対しては取扱説明書でお答えしています。

Handling Instructions

他に質問がある場合は、お気軽にお問い合わせください。

  • * 必須

よくある質問(FAQ)

  • 質問1:

    Is S1200 a racemic mixture or a monomer?

  • 回答:

    S1200 is R form

DNA Methyltransferaseシグナル伝達経路

Tags: Decitabineを買う | Decitabine ic50 | Decitabine供給者 | Decitabineを購入する | Decitabine費用 | Decitabine生産者 | オーダーDecitabine | Decitabine化学構造 | Decitabine分子量 | Decitabine代理店
×
細胞株 試験類型 濃度 培養時間 溶剤類型 活性叙述 PMID